{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:53:48Z","timestamp":1787756028835,"version":"build-2784847793"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key National Research Projects on Prevention and Control of Major Chronic Non-communicable Disease","award":["2018YFC1312300"],"award-info":[{"award-number":["2018YFC1312300"]}]},{"name":"Fund of science and technology development project of Jilin province","award":["20180414041GH"],"award-info":[{"award-number":["20180414041GH"]}]},{"name":"Jilin Health Technology Innovation Project","award":["2019J003"],"award-info":[{"award-number":["2019J003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antibodies against the 65-kDa isoform of glutamic acid decarboxylase (GAD65) are biomarkers of autoimmune disorders and are more common in non-neurological autoimmune diseases than in neurological disorders. As for the central nervous system (CNS), it is well known that GAD65 is primarily associated with stiff-person syndrome, cerebellar ataxia, epilepsy, and paraneoplastic neurological syndrome. However, GAD65 antibodies have not been reported in patients with brain tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>This study presents the case of a 62-year-old man who manifested rapidly progressive dizziness with gradually worsening physical disturbance and unstable gait in the 2\u00a0months prior to consultation. Antibodies against GAD65 were detected in his serum. Brain magnetic resonance imaging (MRI) showed abnormal signals in the corpus callosum, the semi-oval center in both hemispheres, and the area below the frontal cortex, along with enhanced intracranial lesions in the same regions. Positron emission tomography\u2013computed tomography (PET\u2013CT) showed high metabolism in the corpus callosum, which protruded into both ventricles. Due to signs of malignancy, the patient was diagnosed with a malignant glioma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This case raises awareness on the fact that anti-GAD65 antibodies may be associated with CNS neoplastic lesions. Early recognition of anti-GAD antibodies could be of great importance for the early diagnosis and targeted treatment of neoplastic lesions, and could lead to better prognosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-022-00674-3","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T10:21:14Z","timestamp":1649240474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Are anti-glutamic acid decarboxylase 65-kDa isoform antibodies related to diabetes or brain tumor?"],"prefix":"10.1186","volume":"27","author":[{"given":"Buajieerguli","family":"Maimaiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salamaitiguli","family":"Mijiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6418-7300","authenticated-orcid":false,"given":"Hongmei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"674_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaut.2011.05.005","volume":"37","author":"F Ali","year":"2011","unstructured":"Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun. 2011;37:79\u201387. https:\/\/doi.org\/10.1016\/j.jaut.2011.05.005.","journal-title":"J Autoimmun"},{"key":"674_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaut.2019.04.007","volume":"101","author":"JF Baizabal-Carvallo","year":"2019","unstructured":"Baizabal-Carvallo JF. The neurological syndromes associated with glutamic acid decarboxylase antibodies. J Autoimmun. 2019;101:35\u201347. https:\/\/doi.org\/10.1016\/j.jaut.2019.04.007.","journal-title":"J Autoimmun"},{"key":"674_CR3","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1093\/brain\/awn183","volume":"131","author":"A Saiz","year":"2008","unstructured":"Saiz A, Blanco Y, Sabater L, Gonz\u00e1lez F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553\u201363. https:\/\/doi.org\/10.1093\/brain\/awn183.","journal-title":"Brain"},{"key":"674_CR4","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","volume":"72","author":"H Ari\u00f1o","year":"2015","unstructured":"Ari\u00f1o H, H\u00f6ftberger R, Gresa-Arribas N, Mart\u00ednez-Hern\u00e1ndez E, Armangue T, Kruer MC, et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol. 2015;72:874\u201381. https:\/\/doi.org\/10.1001\/jamaneurol.2015.0749.","journal-title":"JAMA Neurol"},{"key":"674_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10072-021-05281-4","volume":"43","author":"L Lacruz-Ballester","year":"2022","unstructured":"Lacruz-Ballester L, Fernandez-Fournier M, Puertas-Mu\u00f1oz I, Rodriguez-Fraga O, LastrasFernandez-Escandon C, RodriguezdeRiveraGarrido FJ, et al. Serum glutamate decarboxylase antibodies and neurological disorders: when to suspect their association? Neurol Sci. 2022;43:633\u201341. https:\/\/doi.org\/10.1007\/s10072-021-05281-4.","journal-title":"Neurol Sci"},{"key":"674_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s10072-019-3701-6","volume":"40","author":"SM Villa","year":"2019","unstructured":"Villa SM, Rufa A, Malandrini A, Cerase A, Rosini F, Arrigucci U, et al. Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report. Neurol Sci. 2019;40:1303\u20136. https:\/\/doi.org\/10.1007\/s10072-019-3701-6.","journal-title":"Neurol Sci"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0065-2776(08)00803-1","volume":"100","author":"R Uibo","year":"2008","unstructured":"Uibo R, Lernmark A. GAD65 autoimmunity-clinical studies. Adv Immunol. 2008;100:39\u201378. https:\/\/doi.org\/10.1016\/S0065-2776(08)00803-1.","journal-title":"Adv Immunol"},{"key":"674_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1471-4159.2006.03741.x","volume":"97","author":"AB Patel","year":"2006","unstructured":"Patel AB, de Graaf RA, Martin DL, Battaglioli G, Behar KL. Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo. J Neurochem. 2006;97:385\u201396. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.03741.x.","journal-title":"J Neurochem"},{"key":"674_CR9","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"A Katsarou","year":"2017","unstructured":"Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. https:\/\/doi.org\/10.1038\/nrdp.2017.16.","journal-title":"Nat Rev Dis Primers"},{"key":"674_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","volume":"16","author":"KS Husari","year":"2019","unstructured":"Husari KS, Dubey D. Autoimmune epilepsy. Neurotherapeutics. 2019;16:685\u2013702. https:\/\/doi.org\/10.1007\/s13311-019-00750-3.","journal-title":"Neurotherapeutics"},{"key":"674_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.25565","volume":"56","author":"A McKeon","year":"2017","unstructured":"McKeon A, Tracy JA. GAD65 neurological autoimmunity. Muscle Nerve. 2017;56:15\u201327. https:\/\/doi.org\/10.1002\/mus.25565.","journal-title":"Muscle Nerve"},{"key":"674_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(18)30990-5","volume":"392","author":"S Lapointe","year":"2018","unstructured":"Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018;392:432\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(18)30990-5.","journal-title":"Lancet"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.nic.2016.06.006","volume":"26","author":"A Mohammadzadeh","year":"2016","unstructured":"Mohammadzadeh A, Mohammadzadeh V, Kooraki S, Sotoudeh H, Kadivar S, Shakiba M, et al. Pretreatment evaluation of glioma. Neuroimaging Clin N Am. 2016;26:567\u201380. https:\/\/doi.org\/10.1016\/j.nic.2016.06.006.","journal-title":"Neuroimaging Clin N Am"},{"key":"674_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41568-019-0226-5","volume":"20","author":"J Bi","year":"2020","unstructured":"Bi J, Chowdhry S, Wu S, Zhang W, Masui K, Mischel PS. Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets. Nat Rev Cancer. 2020;20:57\u201370. https:\/\/doi.org\/10.1038\/s41568-019-0226-5.","journal-title":"Nat Rev Cancer"},{"key":"674_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/sj.bjc.6601269","volume":"89","author":"TN Seyfried","year":"2003","unstructured":"Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89:1375\u201382. https:\/\/doi.org\/10.1038\/sj.bjc.6601269.","journal-title":"Br J Cancer"},{"key":"674_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nature14363","volume":"520","author":"D Kim","year":"2015","unstructured":"Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015;520:363\u20137. https:\/\/doi.org\/10.1038\/nature14363.","journal-title":"Nature"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-022-00674-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-022-00674-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T10:26:18Z","timestamp":1649240778000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-022-00674-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s40001-022-00674-3","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Research Ethics Board of the First Hospital of Jilin University. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.Written informed consent was obtained from the patient and his family for his participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient and her family to publish this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}